Enlivex Therapeutics

Company Overview

Snapshot

Founded in September 2005 by Prof. Dror Mevorach, Enlivex Therapeutics operates with 11–50 employees. The company has raised over $286.9 million across 11 funding rounds from 5 investors. In November 2025, Enlivex Therapeutics raised $212 million in a PIPE funding round.

Business overview

Enlivex Therapeutics is a clinical-stage company specializing in macrophage reprogramming cell therapies. The company develops and commercializes a drug pipeline aimed at macrophage reprogramming for various indications, including solid cancers, sepsis, and COVID-19. Its primary product candidate, Allocetra, focuses on reprogramming diseased macrophages and has demonstrated positive safety, tolerability, and efficacy in clinical trials for sepsis and COVID-19. Enlivex Therapeutics operates within the Health Tech & Life Sciences sector, specifically targeting Pharmaceuticals and Biotechnology markets.

Strategic signal

In November 2025, Enlivex Therapeutics announced positive 6-month topline data for Allocetra in patients with moderate to severe knee osteoarthritis, demonstrating durable pain reduction and improved function. This clinical validation for a new indication signals potential expansion beyond its initial focus on sepsis and COVID-19, indicating a broader therapeutic applicability and market opportunity for its macrophage reprogramming technology.

Company Intelligence Q&A

What was a significant recent development regarding Allocetra for osteoarthritis?

In November 2025, Enlivex Therapeutics announced positive 6-month topline data for Allocetra, demonstrating durable and persistent pain reduction and improved function in primary age-related patients with moderate to severe knee osteoarthritis.

What authorization did Enlivex receive for its osteoarthritis trial in September 2024?

In September 2024, Enlivex Therapeutics received authorization from the Danish Medicines Agency to initiate the Phase II stage of its Phase I/II trial of Allocetra in patients with moderate to severe knee osteoarthritis.

What patent application was issued to Enlivex in September 2025?

In September 2025, Enlivex Therapeutics announced the issuance of a new patent application covering the use of Allocetra in patients with osteoarthritis.

What was a key strategic leadership appointment in November 2025?

In November 2025, Enlivex Therapeutics appointed Mr. Matteo Renzi, former Prime Minister of Italy, to its board of directors.

What was the outcome of the merger with Bioblast Pharma?

In March 2019, Enlivex Therapeutics completed its merger with Tel Aviv-headquartered Bioblast Pharma. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was then renamed Enlivex Therapeutics.